Abstract
Insulin resistance is an important risk factor of cardiovascular disease. This study was performed to determine the effects of valsartan on insulin sensitivity in patients with primary hypertension. In this study, non-obese subjects with primary hypertension and a reference group of healthy subjects matched by age, sex and body mass index were evaluated; patients with any other causes of peripheral insulin resistance and hyperlipidaemia were excluded. The effect of valsartan on insulin resistance, assessed by homeostasis model assessment (HOMA-IR), fasting serum insulin levels, determined by radioimmunoassay, and fasting blood glucose concentrations, measured by the glucose oxidase method, were evaluated. All obtained data were evaluated by Pearson correlation analysis. Before valsartan treatment, the fasting serum insulin levels were significantly elevated in the 20 hypertensive patients with primary hypertension compared with the 20 subjects in the reference group (19.6 +/- 7.1 versus 8.7 +/- 1.9 microIU/ml). The fasting serum insulin levels correlated with HOMA-IR. Correlation analysis also showed a significant relationship between HOMA-IR and both systolic and diastolic blood pressures (r = 0.71 and r = 0.77, respectively)....Continue Reading
References
Apr 1, 1975·The Journal of Clinical Investigation·R A DeFronzoP J Davis
Sep 1, 1992·Diabetologia·C BerneP Hjemdahl
Feb 1, 1991·Journal of Internal Medicine·K LandinU Smith
Feb 1, 1991·American Journal of Hypertension·M W BrandsJ E Hall
May 1, 1990·Hypertension·J E HallC A Gaillard
Mar 1, 1989·American Journal of Hypertension·J E HallH L Mizelle
Aug 6, 1987·The New England Journal of Medicine·E FerranniniS Bevilacqua
Sep 1, 1987·Diabetologia·E BonoraU Butturini
Mar 1, 1985·The Journal of Clinical Investigation·M ModanZ Fuchs
Sep 1, 1985·Hypertension·C P LucasG M Reaven
Jun 1, 1982·The Journal of Clinical Investigation·C LiangW B Hood
Mar 1, 1981·Diabetes·J W RoweL Landsberg
Oct 1, 1982·Ophthalmology·J B Walsh
Aug 25, 1995·European Journal of Pharmacology·L ChowN Levens
Feb 1, 1993·Hypertension·E A Anderson, A L Mark
Jan 14, 1997·European Journal of Pharmacology·L ChowN Levens
Apr 1, 1999·Journal of Hypertension·F GallettiM Mancini
Aug 18, 1999·Cardiology·S Julius
Jun 1, 2000·American Journal of Hypertension·K A Jamerson
Jun 17, 2000·Diabetes Care·E BonoraM Muggeo
Feb 24, 2001·Hypertension·Jacobine M. A. van AmptingErik S. G. Stroes
Mar 7, 2001·Hypertension·Z J ChengE M Mervaala
Jul 18, 2001·Circulation·H DuplainU Scherrer
Jul 24, 2001·Blood Pressure. Supplement·G G Belz
Oct 31, 2001·Blood Pressure. Supplement·T Unger
Citations
Sep 8, 2010·Psychopharmacology·Hakuei YamashitaTaeko Maruki
Mar 29, 2005·Vascular Pharmacology·Nana GletsuKenneth E Bernstein
Nov 26, 2009·International Journal of Clinical Practice·K G ParhoferA Ptaszynska
Oct 2, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·James E Frampton, Lesley J Scott
Jan 6, 2009·The Journal of Clinical Hypertension·Dion H ZappeDomenic A Sica
Oct 7, 2011·The Journal of Clinical Hypertension·Kevin E C MeyersVictor Shi
Apr 27, 2011·Journal of the American Academy of Nurse Practitioners·Margaret A Fitzgerald
Oct 24, 2008·American Heart Journal·Robert M CaliffUNKNOWN NAVIGATOR Study Group
Sep 17, 2005·The American Journal of Medicine·Prakash C Deedwania, Vivian A Fonseca
Dec 1, 2012·European Journal of Pharmacology·Kentarou UshijimaAkio Fujimura
Aug 30, 2005·Blood Pressure·Luis M RuilopeFaiez Zannad
Mar 18, 2010·The Journal of International Medical Research·J-M LeeS-A Chang
May 23, 2008·Diabetes, Obesity & Metabolism·Hussam Abuissa, James O'Keefe
Nov 17, 2009·Drugs·Henry R BlackRita Samuel
Nov 2, 2004·Drugs·André J Scheen
Mar 27, 2003·Journal of Hypertension·Paul ChanJuei-Tang Cheng
Aug 8, 2007·Journal of the Cardiometabolic Syndrome·Po Sing Leung, Marc de Gasparo
Apr 2, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Kenneth S Hershon